http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201792356-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-06 |
| filingDate | 2016-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201792356-A1 |
| titleOfInvention | AGONISTS OF RECEPTOR 5-HTI OF THEIR COMPOSITIONS AND METHODS OF USE |
| abstract | In the present description in some embodiments, the implementation presents the connection. Also in some embodiments, methods for controlling weight, inducing satiety and reducing food intake, as well as preventing and treating obesity, induced by antipsychotic weight gain, type II diabetes, Prader-Willi syndrome, tobacco / nicotine addiction, drug addiction, alcohol addiction, pathological gambling, lack of remuneration syndrome and sexual addiction, obsessive-compulsive spectrum disorders and impulse control disorders (including nibbling tei and oniophagia), sleep disturbances (including insomnia, fragmented sleep architecture and slow-wave sleep disorders), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa and bulimia nervosa), Alzheimer's disease, impaired sexual function, erectile dysfunction, epilepsy, motor disorders (including parkinsonism and antipsychotic-induced motor impairment), hypertension, dyslipidemia, non-alcoholic liver obesity, kidney disease associated with obesity, and apnea in a dream. Also in some embodiments, compositions are presented that contain a compound in the present description, optionally in combination with an additional agent, and methods for reducing the frequency of tobacco smoking in an individual attempting to reduce the frequency of tobacco smoking; facilitating the refusal or reduction of the use of a tobacco product by an individual trying to stop or reduce the use of a tobacco product; promoting smoking cessation and preventing associated weight gain; controlling the weight gain associated with quitting an individual trying to stop smoking tobacco; reducing the weight gain associated with quitting an individual trying to stop smoking tobacco; treatment of nicotine addiction, addiction and / or withdrawal syndrome in an individual trying to cure nicotine addiction, addiction and / or withdrawal syndrome; or reduce the likelihood of recurrence of nicotine use by an individual trying to stop using nicotine, which includes administering the compound in the present description, optionally in combination with an additional agent. |
| priorityDate | 2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID89594 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556542 |
Total number of triples: 16.